Search Results

Filter
  • 1-10 of  83,465 results for ""Ritonavir""
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Safety profile of nirmatrelvir-ritonavir: Evidence of adverse events due to drug-drug interactions.

Subjects: Lactams* ; Leucine* ; Nitriles*

  • Source: Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria [Farm Hosp] 2024 Mar-Apr; Vol. 48 (2), pp. 70-74. Date of Electronic Publisher: Elsevier España Country of Publication: Spain NLM ID: 9440679 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Clinical effectiveness of nirmatrelvir plus ritonavir on the short- and long-term outcome in high-risk children with COVID-19.

  • Authors : Wu JY; Department of Nutrition, Chi Mei Medical Center, Tainan, Taiwan.; Department of Public Health, College of Medicine, National Cheng Kung University, Tainan, Taiwan.

Subjects: Ritonavir*/Ritonavir*/Ritonavir*/therapeutic use ; COVID-19 Drug Treatment* ; COVID-19*/COVID-19*/COVID-19*/mortality

  • Source: Journal of medical virology [J Med Virol] 2024 May; Vol. 96 (5), pp. e29662.Publisher: Wiley-Liss Country of Publication: United States NLM ID: 7705876 Publication Model: Print Cited Medium: Internet ISSN: 1096-9071

Record details

×
Academic Journal

Safety and Pharmacokinetics of Lopinavir/Ritonavir Oral Solution in Preterm and Term Infants Starting Before 3 Months of Age.

  • Authors : Bekker A; From the Family Centre for Research with Ubuntu, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa.; Yang J

Subjects: HIV Protease Inhibitors*/HIV Protease Inhibitors*/HIV Protease Inhibitors*/adverse effects ; HIV Protease Inhibitors*/HIV Protease Inhibitors*/HIV Protease Inhibitors*/pharmacokinetics ; Lopinavir*/Lopinavir*/Lopinavir*/adverse effects

  • Source: The Pediatric infectious disease journal [Pediatr Infect Dis J] 2024 Apr 01; Vol. 43 (4), pp. 355-360. Date of Electronic Publication: 2024 Jan 04.Publisher: Williams & Wilkins Country of Publication: United States NLM ID: 8701858 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Report

Effectiveness of nirmatrelvir-ritonavir on severe outcomes of COVID-19: A meta-regression analysis.

  • Authors : Chen IW; Department of Anesthesiology, Chi Mei Medical Center, Liouying, Tainan City, Taiwan.; Yu TS

Subjects: Antiviral Agents*/Antiviral Agents*/Antiviral Agents*/therapeutic use ; COVID-19 Drug Treatment* ; Ritonavir*/Ritonavir*/Ritonavir*/therapeutic use

  • Source: Journal of medical virology [J Med Virol] 2024 Jun; Vol. 96 (6), pp. e29718.Publisher: Wiley-Liss Country of Publication: United States NLM ID: 7705876 Publication Model: Print Cited Medium: Internet ISSN: 1096-9071

Record details

×
Academic Journal

Physiologically based Pharmacokinetic Model Validated to Enable Predictions Of Multiple Drugs in a Long-acting Drug-combination Nano-Particles (DcNP): Confirmation with 3 HIV Drugs, Lopinavir, Ritonavir, and Tenofovir in DcNP Products.

  • Authors : Perazzolo S; Department of Pharmaceutics, University of Washington, Seattle, WA 98195-7610, USA. Electronic address: .; Shen DD

Subjects: Ritonavir*/Ritonavir*/Ritonavir*/pharmacokinetics ; Ritonavir*/Ritonavir*/Ritonavir*/administration & dosage ; Lopinavir*/Lopinavir*/Lopinavir*/pharmacokinetics

  • Source: Journal of pharmaceutical sciences [J Pharm Sci] 2024 Jun; Vol. 113 (6), pp. 1653-1663. Date of Electronic Publication: 2024 Feb 20.Publisher: Elsevier Country of Publication: United States NLM ID: 2985195R Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Nirmatrelvir/ritonavir treatment of patients with COVID-19 taking tacrolimus: case series describing the results of drug-drug interactions.

  • Authors : Shen D; Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Su Zhou, People's Republic of China.; Gong Y

Subjects: Ritonavir*/Ritonavir*/Ritonavir*/therapeutic use ; Tacrolimus*/Tacrolimus*/Tacrolimus*/therapeutic use ; Tacrolimus*/Tacrolimus*/Tacrolimus*/adverse effects

  • Source: The Journal of international medical research [J Int Med Res] 2024 May; Vol. 52 (5), pp. 3000605241247705.Publisher: Sage Publications Country of Publication: England NLM ID: 0346411 Publication Model: Print Cited Medium: Internet ISSN: 1473-2300

Record details

×
Academic Journal

Effectiveness of Nirmatrelvir-Ritonavir for the Prevention of COVID-19-Related Hospitalization and Mortality: A Systematic Literature Review.

Subjects: Antiviral Agents*/Antiviral Agents*/Antiviral Agents*/therapeutic use ; COVID-19 Drug Treatment* ; Drug Combinations*

  • Source: American journal of therapeutics [Am J Ther] 2024 May-Jun 01; Vol. 31 (3), pp. e246-e257. Date of Electronic Publication: 2024 Apr 29.Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 9441347 Publication Model: Print-Electronic Cited Medium:

Record details

×
Academic Journal

Time Course of the Interaction Between Oral Short-Term Ritonavir Therapy with Three Factor Xa Inhibitors and the Activity of CYP2D6, CYP2C19, and CYP3A4 in Healthy Volunteers.

  • Authors : Rohr BS; Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Medical Faculty of Heidelberg, Heidelberg University Hospital, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.; Krohmer E

Subjects: Ritonavir*/Ritonavir*/Ritonavir*/administration & dosage ; Ritonavir*/Ritonavir*/Ritonavir*/pharmacokinetics ; Ritonavir*/Ritonavir*/Ritonavir*/pharmacology

  • Source: Clinical pharmacokinetics [Clin Pharmacokinet] 2024 Apr; Vol. 63 (4), pp. 469-481. Date of Electronic Publication: 2024 Feb 23.Publisher: Country of Publication: Switzerland NLM ID: 7606849 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-1926

Record details

×
Academic Journal

Nirmatrelvir and ritonavir combination against COVID-19 caused by omicron BA.2.2 in the elderly: A single-center large observational study.

  • Authors : Chen C; Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, China.; Li R

Subjects: Ritonavir*/Ritonavir*/Ritonavir*/therapeutic use ; COVID-19*; Aged

  • Source: Immunity, inflammation and disease [Immun Inflamm Dis] 2024 Apr; Vol. 12 (4), pp. e1232.Publisher: John Wiley and Sons Ltd Country of Publication: England NLM ID: 101635460 Publication Model: Print Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Effectiveness of nirmatrelvir/ritonavir in children and adolescents aged 12-17 years following SARS-CoV-2 Omicron infection: A target trial emulation.

  • Authors : Wong CKH; Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China. .; Laboratory of Data Discovery for Health (D24H), Hong Kong SAR, China. .

Subjects: Ritonavir*/Ritonavir*/Ritonavir*/therapeutic use ; COVID-19 Drug Treatment* ; SARS-CoV-2* pediatric multisystem inflammatory disease, COVID-19 relatedSARS-CoV-2 variants

  • Source: Nature communications [Nat Commun] 2024 Jun 08; Vol. 15 (1), pp. 4917. Date of Electronic Publication: 2024 Jun 08.Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN:

Record details

×
  • 1-10 of  83,465 results for ""Ritonavir""